#WCLC25 It takes a village! Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social! @jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR

🚨 Breaking from #WCLC25: Final OS results from the FLAURA2 trial. 🔗 Read the highlights from the first Presidential Symposium in ILCN: bit.ly/48l4oU2 #LCSM

A fresh episode of LCC is out! Dr. Alona Zer moderates a conversation with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel on the major takeaways from #WCLC25, including clinical advances, research highlights, and global perspectives on lung cancer. Start Listening: bit.ly/48l1M8E

Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC. 🔗 More in ILCN: bit.ly/4nyjauW

What were the biggest research stories at #WCLC2025? In this Mandarin episode of Lung Cancer Considered, Dr. Chunxia Su speaks with Dr. Yang Xia and Dr. Nan Bi about the most impactful findings from this year’s conference. 🎧 Listen here: bit.ly/3Il284D #IASLC #LungCancer #WCLC2025 #Oncology

🛎️ Auction extended to Sept 21! Support lung cancer research and score amazing prizes, from a Maui escape to mentoring with Dr. David Carbone. 💙 All proceeds support early-career investigators via the IASLC Foundation. Bid before Sept 21: bit.ly/47H0swO #IASLC #AuctionForACause #LungCancerResearch

What were the key highlights from #WCLC25 on Monday? In this #LungCancerConsidered episode, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social discuss NADIM ADJUVANT, VATS vs lobectomy, and EA5181/LS SCLC results with leading experts. 🎧 bit.ly/WCLC25Mon

⭐ #WCLC25 Presenter Spotlight: Gisele Fraga Moreira will discuss the role of targeted therapies in lung cancer treatment and emphasize the need for a multidisciplinary and personalized approach to managing new toxicities. 🔗 Learn more in ILCN: bit.ly/3JPZPXA #LCSM

📢 Announcing the @iaslc.bsky.social—Lancet Commission: a transformative approach to lung cancer. "Our Commission is determined to frame lung cancer not merely as a disease, but as a global health problem that can be tackled." Read on ⤵️ tinyurl.com/48e7pbrx #WCLC25

⭐ #WCLC25 Presenter Spotlight: Enrica Capelletto, MD, PhD, aims to raise awareness about alternatives to conventional smoking. 🚭 Learn more in ILCN: www.ilcn.org/other-than-c... #LCSM

First time at #WCLC25? 🎉 In this episode of #LungCancerConsidered, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social share 10 tips to help attendees get the most out of the meeting, including how to work in a bit of self-care! 🎧 bit.ly/WCLC1st

The #WCLC25 Opening Plenary recognized the 2025 Distinguished Service Award Recipients. 🔗 Read the highlights in ILCN: bit.ly/3HV8wzs

An interactive #WCLC25 session will explore the evolving challenges of science communication. 🔗 Read a preview in ILCN: www.ilcn.org/tackling-the...

Exciting news: Thoracic Circle is officially live! 🎉 Our new online community makes it easier than ever to connect, share, and engage with colleagues around the world. Your invite should be in your inbox — or you can join now at community-iaslc.org.

Kelly Nevins, IASLC Director of Education, says the Amazing Case Race at #WCLC25 puts education in the hands of learners. 🔗 Read the preview in ILCN: www.ilcn.org/third-annual... #LCSM

On a new episode of Lung Cancer Considered, Dr. Chunxia Su hosts a Virtual Tumor Board in Mandarin with Drs. Zhengfei Zhu & Nan Wu. They explore neoadjuvant and perioperative therapy for locally advanced NSCLC in China. 🎧 bit.ly/Neoadjuvanta...

WCLC Conference Chair Dr. Noemí Reguart discusses how this year's #WCLC25 program builds on multidisciplinary collaboration and global perspectives in thoracic oncology. 🔗 Read more in ILCN: bit.ly/4lJNcdV #LCSM

On a new episode of Lung Cancer Considered, Dr. @stephenvliu.bsky.social & Dr. @narjustflorezmd.bsky.social talk with Summer Farmen, Nancee Pronsati & Kirk Smith about highlights from the ALK+ Summit, advocacy, and the power of community in lung cancer. 🎧 bit.ly/ALKSummit

In this episode of #LungCancerConsidered in Greek, @drgreeklungcancer.bsky.social hosts Dr. Petros Christopoulos and Dr. Dionysis Papadatos-Pastos to discuss how ALK+ NSCLC is managed in Greece. 🎧 bit.ly/GreekALKVTB #ALK #NSCLC

🎙️On a new episode of Lung Cancer Considered, host @narjustflorezmd.bsky.social speaks with @biagioricciutimd.bsky.social & @drgreeklungcancer.bsky.social about resistance to immune checkpoint inhibitors, STK11/KEAP1/KRAS co-mutations, and emerging NSCLC therapies. bit.ly/LCCColdTumors

Don’t miss out, Early Bird ends Sept 5! Join us in Chicago, Dec 5–7, for #NACLC25 and be part of the conversations shaping the future of lung cancer care. Lock in the best rate now: bit.ly/4mIVmV1 @ascocancer.bsky.social #LungCancer #Oncology #MedicalConference

At the IASLC 2025 Hot Topic Meeting, we’re diving into the biology, biomarkers, and breakthroughs that can transform prevention and treatment. Join the conversation shaping the future of lung cancer research. Register now: bit.ly/4oEkZIq #LungCancerResearch #Oncology #HT25

In this episode of #LungCancerConsidered in Arabic, @naglaakarimmd.bsky.social talks with Dr. Asrar AlAhmadi and Dr. Maya Khalil about the experiences and career paths of Arabic women in thoracic oncology. 🎧 Listen now: bit.ly/ArabWomenTO

Can AI transform lung cancer care? In the newest episode of #LungCancerConsidered, @stephenvliu.bsky.social speaks with @arselaprelaj.bsky.social about how artificial intelligence is changing research, diagnostics & treatment in thoracic oncology. 🎧 bit.ly/AIandLCResea...

𝐁𝐫𝐢𝐧𝐠 𝐘𝐨𝐮𝐫 𝐕𝐢𝐬𝐢𝐨𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐭𝐚𝐠𝐞! #IASLC is seeking dynamic teams of North American members to #co-chair WCLC 2027, in #Denver, CO. Join us in leading the world’s premier #lungcancerconference. Apply by August 6! ➡️ bit.ly/3HfgD9x

Congratulations to IASLC CEO Dr. Karen Kelly for receiving the 2025 Bonnie J. Addario Lectureship Award🎉! This award honors those whose work has profoundly impacted research, education, and patient outcomes in #lungcancer. bit.ly/4mp4bDe @go2forlungcancer.bsky.social #Oncology #CancerResearch

Why does lung cancer carry more stigma than other cancers, & what can we do to change that? On #LungCancerConsidered, @narjustflorezmd.bsky.social, @drcarterbawa.bsky.social & @hawkeyestudts.bsky.social discuss the stigma & how the medical community can help shift the narrative. 🎧 bit.ly/StigmaLCC

🔬 New data from the VERITAS trial demonstrate that NB is a safe and effective alternative to CT-guided transthoracic needle biopsy. 🔗 Read more in ILCN: bit.ly/4md0OPt

The latest episode of #LungCancerConsidered in Japanese explores top #ASCO25 studies, including NEOADAURA, REZILIENT1 & TROPION-Lung02. Dr. Misako Nagasaka hosts with Dr. Yasushi Goto and Dr. Yuko Oya from Japan. 🎧 bit.ly/ASCO25Japanese

#NACLC25 is open! Registration & abstracts are live for Dec 5–7, 2025, in Chicago. Hear from co‑chairs @kamarronemd.bsky.social & Ramesh Rengan, MD, PhD, FASTRO on Lung Cancer Considered—insights, highlights & why you should be there. 🎧 bit.ly/NACLC25Preview #LungCancer @ascocancer.bsky.social

Brustugun et al. walk us through the surgical approaches, radiation approaches, systemic therapy, and more related to lung cancer in #Norway in this contribution to Lung Cancer Worldwide. Read now ➡️ bit.ly/44Qr5vS

📢The FDA just approved datopotamab deruxtecan for advanced EGFR+ NSCLC. In this week’s #LungCancerConsidered, @narjustflorezmd.bsky.social is joined by Dr. Jacob Sands to break down the approval and its impact on care. 🎧 bit.ly/LCCdatadive #NSCLC

Tomorrow is the last day to register for #WCLC2025 at a discounted rate! Join lung cancer experts from around the world September 6-9 in Barcelona. Don’t miss your chance to be part of the conversation. 🔗 bit.ly/4nSE0X3 #IASLC #WCLC #LungCancer #CancerCare #Oncology #Barcelona2025 #GlobalOncology

What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy. 🎧 bit.ly/FDAexon20

Abstract deadline extended for #ACLC2025! You now have until July 18 to share your research. 📍Join us in Ho Chi Minh City, Vietnam | Oct 9–11 Submit now ➡️ bit.ly/44JZHzQ #LungCancer #OncologyResearch #GlobalHealth #MedicalConference #CallForAbstracts

In this episode of #LungCancerConsidered, we're exploring the treatment of EGFR+ NSCLC. @clarissamathias.bsky.social leads a discussion in Portuguese with Dr. Guilherme Harada and Dr. William N. William. 🎧 Listen: bit.ly/VTBport #EGFR #NSCLC #Oncology

Security Incident on IASLC's X Account We want to inform our community that our official X account, @IASLC, was compromised earlier today. We have taken immediate steps to regain control. Disregard any posts, messages, or links shared at this time. ❓❓, please contact us at [email protected]

🔬 Research to watch: ZL-1310 earns #FDA Fast Track as a potential first-in-class DLL3-targeted ADC for ES-SCLC. 🔗 Full details in ILCN: bit.ly/3TfeU6z #LCSM #IASLC

🚨 Breaking: Final OS results from the CheckMate816 trial confirm the benefit of neoadjuvant-only chemotherapy. 🔗 Dr. Patrick Forde shares the data in ILCN: bit.ly/4kXXzLC #ASCO25 #LCSM

What’s the best approach to resectable EGFR-mutant NSCLC? In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario. 🎧 bit.ly/VTBregfrnsclc #NSCLC #EGFR

🚨Don’t miss our upcoming webinar! The Lung Cancer Patient Journey Across the World 🗓️ July 3 | 🕐 9:30 AM MDT/ 3:30 PM UTC Hear from a multidisciplinary panel as they explore regional perspectives and challenges in lung cancer care. 🔗 Register now: bit.ly/3I8PMw3 #LungCancer #GlobalOncology #IASLC

Han et al. evaluated 105 patients with advanced EGFR-mutated NSCLC while treating them with TY-9591, a deuterated osimertinib derivative, in this dose-escalation and dose-expansion study. They found that TY-9591 reported favorable safety and substantial efficacy. Check it out: bit.ly/4dUc2p9

FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. Learn more ➡️ bit.ly/44fIz4B #FDAApproval #AcceleratedApproval #OncologyNews #LungCancerTreatment #CancerResearch

A new ROS1+ NSCLC therapy is here. In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care. 🎧 Tune in here: bit.ly/FDATaletrect... #IASLC #NSCLC

In a new episode of #LungCancerConsidered, @narjustflorezmd.bsky.social talks with Claudia Proto and @chulkimmd.bsky.social about the evolving treatment options for thymoma and thymic carcinoma. 🎧 Listen now: bit.ly/ThymustalkLCC #LungCancer #IASLC

📅 Save the date! Join global experts in Tokyo, Japan for the IASLC 2025 Hot Topic Meeting on November 21–23, 2025. 🔬 Dive deep into early-stage lung cancer research, biomarkers, and new diagnostic breakthroughs. Details 👉 fallht-iaslc.org #IASLC #LungCancer #EarlyDetection #TranslationalScience

Dr. David Spigel says a 14-gene molecular assay may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery. 🔗 Read more: bit.ly/4nk63hW

2024 Impact Factor updates from IASLC! JTO: IF 20.8 🎯 #3 in Respiratory Medicine #13 in Oncology (of 326!) JTO CRR: IF up to 3.5 📈 Explore the latest from our journals 👉🏽 bit.ly/3ZGbIol #LungCancer #Oncology #IASLC #ImpactFactor

ICYMI: Telisotuzumab vedotin-tllv receives accelerated FDA approval for advanced NSCLC with high c-Met overexpression. More in ILCN: bit.ly/43IlNUd

Join the IASLC 2025 ASCO Highlights webinar on June 27 for expert insights into the latest breakthroughs in lung cancer treatment. 👉 Register now: bit.ly/4n93NKk #IASLC #ASCO2025 #LungCancer #Oncology #CancerResearch #ThoracicOncology #MedicalEducation @ascocancer.bsky.social